MedTrace Logo

SIROOP Registry - a Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated with SIROlimus or Paclitaxel Eluting Balloon Catheters

NCT04988685 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-10-29

No results posted yet for this study

Summary

The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.

Conditions

  • Coronary Disease
  • Coronary Artery Disease
  • Coronary Restenosis
  • Coronary Arteriosclerosis
  • Coronary Artery Calcification
  • Stable Chronic Angina
  • Angina Pectoris
  • Angina, Stable
  • Angina, Unstable
  • Stent Thrombosis

Interventions

DEVICE

Sirolimus Eluting Balloon

PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon

Sponsors & Collaborators

  • University Hospital, Geneva

    collaborator OTHER

  • Luzerner Kantonsspital

    lead OTHER

Principal Investigators

  • Florim Cuculi, MD · Luzerner Kantonsspital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2026-12-31
Completion
2031-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04988685 on ClinicalTrials.gov